CXCL13 as a biomarker in the diagnostics of European lyme Neuroborreliosis - A prospective multicentre study in Austria.

Christoph WaißBarbara StröbeleUwe GraichenSascha KleeJoshua GartlehnerEstelle SonntagbauerStephanie HirschbichlerAlexander TinchonEmrah KacarBianca WuchtyBianka NovotnaZofia KühnJohann SellnerWalter StruhalChristian BancherPeter SchniderSusanne Asenbaum-NanStefan Oberndorfer

Published in: Journal of central nervous system disease (2024)

Based on our results, we propose a CSF CXCL13 cut-off of 271 pg/ml with Euroimmun-Elisa for the diagnosis of acute and untreated NB. Due to its high sensitivity and specificity, CXCL13 is a strong candidate biomarker for routine NB assessment, especially in clinically unclear cases.

Keyphrases

liver failure
respiratory failure
clinical practice
drug induced
hepatitis b virus
aortic dissection